An understanding of the biological heterogeneity of acute myeloid leukemia has been gained from studies of morphology, cytogenetics, cell surface antigen expression, level of leukemic transformation, responsiveness to hematopoietic growth factors, in vivo and in vitro differentiation, and protooncogene expression. Knowledge acquired from these studies has begun to lead to stratification of therapy and to new avenues of treatment.